No Data
No Data
Bristol Myers Squibb (BMY) Stock Falls Amid Market Uptick: What Investors Need to Know
Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report
Perspective Falls After Data for Radiopharmaceutical in Skin Cancer
Morgan Stanley Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Maintains Target Price $37
Kyverna, Cabaletta Started at Buys by UBS on CAR T Therapy Potential
Today's Analyst Rating | Alibaba Price Target Raised to $115 by Morgan Stanley, TD Cowen Downgrades PepsiCo to Hold
103811615 : Nyi Nyi Htwe Y324412